Kazemi T, et al. – This paper appraised the efficacy of ixekizumab in the treatment of plaque psoriasis. It was determined that ixekizumab was a highly efficacious, newly Food and Drug Administration (FDA)–approved therapy for moderate–to–severe plaque psoriasis. It brought to light a robust clinical response, prominent improvement in patients' quality of life, and a favorable safety profile.